Viridian Therapeutics (VRDN) Competitors

Fulgent Genetics (NASDAQ:FLGT) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.

Does the MarketBeat Community favor FLGT or VRDN?

Fulgent Genetics received 212 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 65.31% of users gave Viridian Therapeutics an outperform vote while only 61.46% of users gave Fulgent Genetics an outperform vote.

Company	Underperform	Outperform
Fulgent Genetics	Outperform Votes 244 61.46%	Underperform Votes 153 38.54%
Viridian Therapeutics	Outperform Votes 32 65.31%	Underperform Votes 17 34.69%

Does the media favor FLGT or VRDN?

In the previous week, Fulgent Genetics had 2 more articles in the media than Viridian Therapeutics. MarketBeat recorded 2 mentions for Fulgent Genetics and 0 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.04 beat Fulgent Genetics' score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Fulgent Genetics	Positive
Viridian Therapeutics	Neutral

Which has higher earnings and valuation, FLGT or VRDN?

Fulgent Genetics has higher revenue and earnings than Viridian Therapeutics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$307.38M	2.66	$143.40M	-$1.64	-16.66
Viridian Therapeutics	$1.77M	383.41	-$129.87M	-$4.87	-3.19

Do analysts recommend FLGT or VRDN?

Fulgent Genetics currently has a consensus target price of $42.33, indicating a potential upside of 54.95%. Viridian Therapeutics has a consensus target price of $42.57, indicating a potential upside of 173.95%. Given Fulgent Genetics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Viridian Therapeutics	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals have more ownership in FLGT or VRDN?

46.1% of Fulgent Genetics shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Comparatively, 1.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is FLGT or VRDN more profitable?

Fulgent Genetics has a net margin of -15.84% compared to Fulgent Genetics' net margin of -13,462.86%. Viridian Therapeutics' return on equity of -3.29% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-15.84%	-3.29%	-3.03%
Viridian Therapeutics	-13,462.86%	-86.39%	-49.05%

Which has more volatility & risk, FLGT or VRDN?

Fulgent Genetics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Summary

Fulgent Genetics beats Viridian Therapeutics on 12 of the 18 factors compared between the two stocks.